Tejnaksh Healthcare Ltd.
Snapshot View

88.00 +2.15 ▲2.5%

30 July 2021, 04:00:00 P.M.
Volume: 48,829

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Compare with Industry peers
Website http://www.tejnaksh.com
Financial Indicators
Market Cap 89.08 Cr.
Earnings per share (EPS) 2.02 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 43.39 Trailing Twelve Months Ending 2021-03
Industry PE 227.26 Trailing Twelve Months Ending 2021-03
Book Value / Share 17.05 Trailing Twelve Months Ending 2021-03
Price to Book Value 5.14 Calculated using Price: 87.70
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 1.02 Cr. 10,156,800 Shares
FaceValue 10
Company Profile

The company was incorporated in Mumbai as “Tejnaksh Healthcare Private Limited” on February 18, 2008 as a private limited company under provision of companies Act 1956. The company was converted in to a Public Limited Company and consequently the name was changed to “Tejnaksh Healthcare Limited' vide fresh certificate of incorporation dated 10th March, 2015 issued by the Registrar of Companies, Mumbai, Maharashtra. The company’s Managing Director and Promoter Ashish Vishwas Rawandale is listed in Guinness World Records (twice), Ripley’s believe it or not, Limca book of records, India book of records (multiple records), Asia book of records, World amazing records and World record academy for various achievements and innovations in urology.

The company is a professionally managed and growing organization. The company runs an Institute of Urology, an ISO certified the international level Urology hospital, located in the heart of Dhule city, Maharashtra, India. The 24000 Sq. Ft. campus has a four storey building which houses the complete Urology setup. It provides a comprehensive range of services from consultations and investigations to treatment for Urology. The company is equipped with all latest equipment and provides the whole range of services, the patients from local area do not feel the need to go to metropolitan areas for urological problems. The Institute is recognized by National board of examinations for DNB (Urology). The Institute boasts of 150 research publications and 23 innovations.

Business area of the company

The company is an integrated healthcare delivery service provider, committed to delivering quality healthcare services to its patients in modern facilities. Its operations are divided across four key vertical streams in healthcare delivery, namely - “Pediatric Urology”, “Adult Urology (Male, Female)”, “Andrology and Sexual Dysfunction” and “Nephrology, Dialysis and Renal Transplant”. It offers a gamut of more than 65 healthcare services under these streams. A base of over 65 employees and consultants supports its healthcare facility network. The company’s healthcare facilities use advanced technology and its doctors, nurses and other healthcare professionals follow treatment protocols that match international standards. A majority of its healthcare facilities provide secondary, tertiary and quaternary healthcare services to patients. Some of its healthcare facilities provide super speciality quaternary healthcare to patients in key specialty areas such as Pediatric Urology and Adult Urology (Male, Female).

 

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+2.50%
1 Week
+4.76%
1 Month
+29.99%
3 Month
+35.38%
6 Month
+66.82%
1 Year
+141.10%
2 Year
+10.41%
5 Year
+375.93%
5 years 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 21.17 26.68 34.98 26.93 15.10
Return on Capital Employed (%) 34.00 29.35 32.66 27.59 17.78
Return on Assets (%) 19.32 16.96 17.97 14.93 9.10

Balance Sheet View Details

Particulars 5 years 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 6 8 10 13 15
Non Curr. Liab. 0 7 6 6 7
Curr. Liab. 0 1 3 2 2
Minority Int. 0 0 0 0
Equity & Liab. 7 16 20 22 25
Non Curr. Assets 6 14 17 18 18
Curr. Assets 1 2 3 5 7
Misc. Exp. not W/O
Total Assets 7 16 20 22 25

Profit Loss View Details

Particulars 5 years 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 5 7 14 20 17
Other Income 0 0 0 2 1
Total Income 5 7 15 21 17
Total Expenditure -2 -4 -9 -16 -13
PBIDT 2 3 6 6 4
Interest 0 -1 -1 -1
Depreciation 0 0 0 -1 -1
Taxation -1 -1 -1 -1 -1
Exceptional Items
PAT 1 2 3 3 2

Cash Flow View Details

Particulars 5 years 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 4 2 4 3 1
Cash Fr. Inv. -3 -8 -3 -2 -1
Cash Fr. Finan. 0 6 -1 -2 0
Net Change 0 1 1 -1 0
Cash & Cash Eqvt 0 1 2 1 1

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 73.34 73.47 73.67 73.82 73.84 73.84 73.84 73.84 73.84
Public 26.66 26.53 26.33 26.18 26.16 26.16 26.16 26.16 26.16
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Thu, 22 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
In accordance with Regulation 74 (5) of the SEBI (Depositories and Participants) Regulations 2018 Please find enclosed herewith certificate received from Cameo Corporate Services Limited (RTA) for the Quarter ended June 30 2021.

Please take the same on your record.
Sat, 17 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- Prakash Sogam
Designation :- Company Secretary and Compliance Officer
Sat, 17 Jul 2021
Shareholding for the Period Ended June 30 2021
Tejnaksh Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here

Technical Scans View Details

Fri, 30 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month
Strongly Outperforming Benchmark Index Strongly Outperforming Benchmark Index
Strongly Outperforming Sectoral Index Strongly Outperforming Sectoral Index
Close Within 2 Year High Zone Close Within 2 Year High Zone

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,708.53 774.00 +10.1%
Divi's Laboratories Ltd. 129,702.64 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. 78,400.54 4,712.70 +0.9%
Cipla Ltd. 74,235.31 920.30 +4.3%
Cadila Healthcare Ltd. 59,986.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. 57,873.32 4,025.00 -0.3%
Aurobindo Pharma Ltd. 53,701.27 916.50 +0.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 63.95 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 65.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.13 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 30.87 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 28.12 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 384.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.07 916.50 +0.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.00 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 13.95 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.39 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 4.05 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.62 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.60 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.45 916.50 +0.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 0.18 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 916.50 +0.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 10.09 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 916.50 +0.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 12.53 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 916.50 +0.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 17,131.99 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 916.50 +0.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 1,546.98 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 916.50 +0.9%